The hospital looks at the wave of peptide injections, stacks and anti-aging clinics, and weighs the promises against the evidence so far.
Recap by typeshit. Post by @cedarssinai on Instagram.
One study cited by @fittrwithsquats put the risk of non-scarring hair loss about 40% higher with GLP-1 use, mostly telogen effluvium. Nail findings are less consistent.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Women's Health asks researchers what people should know about a more potent GLP-1 medication that is still being tested in trials.
Pink Sheet editors say FDA reviewers warn the peptides lack clinical testing, and some career staff may quit if the order goes ahead.
Loading…